VEGF-C induced by TGF- β1 signaling in gastric cancer enhances tumor-induced lymphangiogenesis

por Pak, Kyung Ho, Park, Ki Cheong, Cheong, Jae-Ho
Publicado 2019

The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells

por Jeon, Jeong Yong, Kim, Seung Won, Park, Ki Cheong, Yun, Mijin
Publicado 2015

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer

por Kim, Seok-Mo, Kim, Soo Young, Park, Cheong Soo, Chang, Hang-Seok, Park, Ki Cheong
Publicado 2020

Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model

por Yun, Hyeok-Jun, Lim, Jin-Hong, Kim, Sang-Yong, Kim, Seok-Mo, Park, Ki-Cheong
Publicado 2022

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma

por Chang, Hang-Seok, Kim, Yonjung, Lee, So Young, Yun, Hyeok Jun, Chang, Ho-Jin, Park, Ki Cheong
Publicado 2023

Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis

por Lim, Jin Hong, Choi, Kyung Hwa, Kim, Soo Young, Park, Cheong Soo, Kim, Seok-Mo, Park, Ki Cheong
Publicado 2020

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer()()

por Choi, Kyung Hwa, Jeon, Jeong Yong, Lee, Young-Eun, Kim, Seung Won, Kim, Sang Yong, Yun, Yeo Jin, Park, Ki Cheong
Publicado 2018

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

por Yun, Hyeok Jun, Kim, Minki, Kim, Sang Yong, Fang, Sungsoon, Kim, Yonjung, Chang, Hang-Seok, Chang, Ho-Jin, Park, Ki Cheong
Publicado 2022

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer

por Kim, Yuna, Yun, Hyeok Jun, Choi, Kyung Hwa, Kim, Chan Wung, Lee, Jae Ha, Weicker, Raymond, Kim, Seok-Mo, Park, Ki Cheong
Publicado 2023

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

por Yun, Hyeok Jun, Kim, Hee Jun, Kim, Jungmin, Kim, Sang Yong, Chang, Hang-Seok, Park, Cheong Soo, Chang, Ho-Jin, Park, Ki Cheong
Publicado 2021

Integrated omics-analysis reveals Wnt-mediated NAD(+) metabolic reprogramming in cancer stem-like cells

por Lee, Jueun, Kee, Hyun Jung, Min, Soonki, Park, Ki Cheong, Park, Sunho, Hwang, Tae Hyun, Ryu, Do Hyun, Hwang, Geum-Sook, Cheong, Jae-Ho
Publicado 2016

Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells()()

por Lee, Yong Sang, Kim, Seok-Mo, Kim, Bup-Woo, Chang, Ho Jin, Kim, Soo Young, Park, Cheong Soo, Park, Ki Cheong, Chang, Hang-Seok
Publicado 2018

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

por Kim, Soo Young, Kim, Seok-Mo, Chang, Ho-Jin, Kim, Bup-Woo, Lee, Yong Sang, Park, Cheong Soo, Park, Ki Cheong, Chang, Hang-Seok
Publicado 2018

Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma

por Lim, Jin Hong, Park, Keunwan, Choi, Kyung Hwa, Kim, Chan Wung, Lee, Jae Ha, Weicker, Raymond, Pan, Cheol-Ho, Kim, Seok-Mo, Park, Ki Cheong
Publicado 2022

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell...

por Park, Ki Cheong, Heo, Jun Hyeok, Jeon, Jeong Yong, Choi, Hye Ji, Jo, A Ra, Kim, Seung Won, Kwon, Ho Jeong, Hong, Sung Joon, Han, Kyung Seok
Publicado 2015

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

por Kim, Seok-Mo, Park, Ki-Cheong, Jeon, Jeong-Yong, Kim, Bup-Woo, Kim, Hyeung-Kyoo, Chang, Ho-Jin, Choi, Seung-Hoon, Park, Cheong-Soo, Chang, Hang-Seok
Publicado 2015

Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma

por Kim, Seok-Mo, Park, Keunwan, Lim, Jin Hong, Yun, Hyeok Jun, Kim, Sang Yong, Choi, Kyung Hwa, Kim, Chan Wung, Lee, Jae Ha, Weicker, Raymond, Pan, Cheol-Ho, Park, Ki Cheong
Publicado 2022

PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models

por Park, Ki Cheong, Kim, Jung Min, Kim, Sang Yong, Kim, Seok-Mo, Lim, Jin Hong, Kim, Min Ki, Fang, Sungsoon, Kim, Yonjung, Mills, Gordon B., Noh, Sung Hoon, Cheong, Jae-Ho
Publicado 2023

Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer

por Park, Ki Cheong, Kim, Seok-Mo, Jeon, Jeong Yong, Kim, Bup-Woo, Kim, Hyeung Kyoo, Chang, Ho Jin, Lee, Yong Sang, Kim, Soo Young, Choi, Seung Hoon, Park, Cheong Soo, Chang, Hang-Seok
Publicado 2017

Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]...

por Park, Ki Cheong, Kim, Seok-Mo, Jeon, Jeong Yong, Kim, Bup-Woo, Kim, Hyeung Kyoo, Chang, HoJin, Lee, Yong Sang, Kim, Soo Young, Choi, Seung Hoon, Park, Cheong Soo, Chang, Hang-Seok
Publicado 2017